Fulminant myocarditis

Nature Clinical Practice Cardiovascular Medicine

Volumn 5, Issue 11, 2008, Pages 693-706

  Gupta, Sachin ^a   Markham, David W ^a   Drazner, Mark H ^a   Mammen, Pradeep P A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALDOSTERONE ANTAGONIST; ALPHA INTERFERON; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE DERIVATIVE; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CEPHALOSPORIN DERIVATIVE; COCAINE; COPPER; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; CREATINE KINASE MB; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GALLIUM 67; IMMUNOGLOBULIN; INDIUM 111; IRON; LEAD; PENICILLIN G; PHENYTOIN; PLACEBO; PREDNISOLONE; SULFONAMIDE; TETRACYCLINE; TROPONIN; UNINDEXED DRUG; VIRUS VACCINE;

ADENOVIRUS; ASPERGILLUS; CARDIOGENIC SHOCK; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; COLD CLAMMY SKIN; CONVALESCENCE; COXSACKIE VIRUS; CYTOMEGALOVIRUS; EARLY INTERVENTION; ECHOCARDIOGRAPHY; ENTERITIS; EOSINOPHILIA; EPSTEIN BARR VIRUS; ERYTHROCYTE SEDIMENTATION RATE; EXTRACORPOREAL OXYGENATION; FLU LIKE SYNDROME; HEART ASSIST DEVICE; HEART FAILURE; HEART MUSCLE BIOPSY; HEART SCINTISCANNING; HEART TRANSPLANTATION; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPOTENSION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; LEUKOCYTOSIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYCOPLASMA PNEUMONIAE; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PARVOVIRUS; PATHOPHYSIOLOGY; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY FAILURE; REVIEW; STREPTOCOCCUS; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA;

BIOPSY; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; HEART FAILURE; HEMODYNAMICS; HUMANS; MYOCARDITIS; MYOCARDIUM; RISK FACTORS; TREATMENT OUTCOME; VIRUS DISEASES;

EID: 55149088326     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1331     Document Type: Review

References (80)

1. Feldman AM et al. (2000) Myocarditis. N Engl J Med 343 1388-1398
2. Magnani JW et al. (2006) Myocarditis: Current trends in diagnosis and treatment. Circulation 113: 876-890
3. Herskowitz A et al. (1993) Demographic features and prevalence of idiopathic myocarditis in patients undergoing endomyocardial biopsy. Am J Cardiol 71: 982-986
4. McCarthy RE III et al. (2000) Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 342: 690-695
5. Mason JW et al. (1995) A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 333: 269-275
6. Hufnagel G et al. (2000) The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). First epidemiological results. Herz 25: 279-285
7. Drory Y et al. (1991) Sudden unexpected death in persons less than 40 years of age. Am J Cardiol 68: 1388-1392
8. Phillips M et al. (1986) Sudden cardiac death in Air Force recruits. A 20-year review. JAMA 256: 2696-2699
9. Grumbach IM et al. (1999) Adenoviruses and enteroviruses as pathogens in myocarditis and dilated cardiomyopathy. Acta Cardiol 54: 83-88
10. Why HJ et al. (1994) Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation 89: 2582-2589
11. Liu P et al. (1996) Viral myocarditis: Balance between viral infection and immune response. Can J Cardiol 12: 935-943
12. Martino TA et al. (1998) Cardiovirulent coxsackieviruses and the decay-accelerating factor (CD55) receptor. Virology 244: 302-314
13. Liu P et al. (2000) The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease. Nat Med 6: 429-434
14. Leiden JM (1997) The genetics of dilated cardiomyopathy-emerging clues to the puzzle. N Engl J Med 337: 1080-1081
15. Towbin JA (1998) The role of cytoskeletal proteins in cardiomyopathies. Curr Opin Cell Biol 10: 131-139
16. Badorff C et al. (1999) Enteroviral protease 2A cleaves dystrophin: Evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 5: 320-326
17. Silver MA et al. (1989) Coronary microvascular narrowing in acute murine coxsackie B3 myocarditis. Am Heart J 118: 173-174
18. Kawai C (1999) From myocarditis to cardiomyopathy: Mechanisms of inflammation and cell death: Learning from the past for the future. Circulation 99: 1091-1100
19. Huber AR et al. (1989) Disruption of the subendothelial basement membrane during neutrophil diapedesis in an in vitro construct of a blood vessel wall. J Clin Invest 83: 1122-1136
20. Harlan JM et al. (1981) Neutrophil-mediated endothelial injury in vitro mechanisms of cell detachment. J Clin Invest 68: 1394-1403
21. Lee JK et al. (1998) A serine elastase inhibitor reduces inflammation and fibrosis and preserves cardiac function after experimentally-induced murine myocarditis. Nat Med 4: 1383-1391
22. Chow LH et al. (1992) Enteroviral infection of mice with severe combined immunodeficiency. Evidence for direct viral pathogenesis of myocardial injury. Lab Invest 66: 24-31
23. Kamijo R et al. (1994) Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 263: 1612-1615
24. Liu P et al. (1995) The role of transgenic knockout models in defining the pathogenesis of viral heart disease. Eur Heart J 16 (suppl 0): 25-27
25. Seko Y et al. (1990) Expression of major histocompatibility complex class I antigen in murine ventricular myocytes infected with coxsackievirus B3. Circ Res 67: 360-367
26. Kaya Z et al. (2001) Contribution of the innate immune system to autoimmune myocarditis: A role for complement. Nat Immunol 2 739-745
27. Ono K et al. (1998) Cytokine gene expression after myocardial infarction in rat hearts: Possible implication in left ventricular remodeling. Circulation 98: 149-156
28. Felker GM et al. (2000) Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol 36: 227-232
29. Dec GW Jr et al. (1985) Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome. N Engl J Med 312: 885-890
30. Smith SC et al. (1997) Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. Circulation 95: 163-168
31. Kato S et al. (2004) Risk factors for patients developing a fulminant course with acute myocarditis. Circ J 68: 734-739
32. Lee CH et al. (2006) Predictive factors of a fulminant course in acute myocarditis. Int J Cardiol 109: 142-145
33. Vignola PA et al. (1984) Lymphocytic myocarditis presenting as unexplained ventricular arrhythmias: Diagnosis with endomyocardial biopsy and response to immunosuppression. J Am Coll Cardiol 4 812-819
34. Cooper LT Jr et al. (1997) Idiopathic giant-cell myocarditis-natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med 336: 1860-1866
35. Cooper LT et al. (2005) Biventricular assist device placement and immunosuppression as therapy for necrotizing eosinophilic myocarditis. Nat Clin Pract Cardiovasc Med 2: 544-548
36. Herzog CA et al. (1984) Acute necrotising eosinophilic myocarditis. Br Heart J 52: 343-348
37. Midei MG et al. (1990) Peripartum myocarditis and cardiomyopathy. Circulation 81: 922-928
38. Zaidi AR et al. (2007) Outcome of heart transplantation in patients with sarcoid cardiomyopathy. J Heart Lung Transplant 26: 714-717
39. Cooper LT Jr (2000) Giant cell myocarditis: Diagnosis and treatment. Herz 25: 291-298
40. Kilgallen CM et al. (1998) A case of giant cell myocarditis and malignant thymoma: A postmortem diagnosis by needle biopsy. Clin Cardiol 21: 48-51
41. Daniels PR et al. (2000) Giant cell myocarditis as a manifestation of drug hypersensitivity. Cardiovasc Pathol 9: 287-291
42. Cooper LT Jr (2005) Giant cell and granulomatous myocarditis. Heart Fail Clin 1: 431-437
43. Newman LS et al. (1997) Sarcoidosis. N Engl J Med 336: 1224-1234
44. Hilfiker-Kleiner D et al. (2007) A cathepsin D-cleaved 16kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128: 589-600
45. Hochman JS et al. (2001) One-year survival following early revascularization for cardiogenic shock. JAMA 285: 190-192
46. Pinamonti B et al. (1988) Echocardiographic findings in myocarditis. Am J Cardiol 62: 285-291
47. Mendes LA et al. (1994) Right ventricular dysfunction: An independent predictor of adverse outcome in patients with myocarditis. Am Heart J 128: 301-307
48. Lieback E et al. (1996) Clinical value of echocardiographic tissue characterization in the diagnosis of myocarditis. Eur Heart J 17: 135-142
49. Carvalho JS et al. (1996) Prognostic value of posterior wall thickness in childhood dilated cardiomyopathy and myocarditis. Eur Heart J 17: 1233-1238
50. Hiramitsu S et al. (2001) Transient ventricular wall thickening in acute myocarditis: A serial echocardiographic and histopathologic study. Jpn Circ J 65: 863-866
51. Gagliardi MG et al. (1991) Usefulness of magnetic resonance imaging for diagnosis of acute myocarditis in infants and children, and comparison with endomyocardial biopsy. Am J Cardiol 68: 1089-1091
52. Gagliardi MG et al. (1999) MRI for the diagnosis and follow-up of myocarditis. Circulation 99: 458-459
53. Mahrholdt H et al. (2004) Cardiovascular magnetic resonance assessment of human myocarditis: A comparison to histology and molecular pathology. Circulation 109: 1250-1258
54. Liu PP et al. (2005) Cardiovascular magnetic resonance for the diagnosis of acute myocarditis: Prospects for detecting myocardial inflammation. J Am Coll Cardiol 45: 1823-1825
55. Hung MY et al. (2007) Use of gallium 67 scintigraphy to differentiate acute myocarditis from acute myocardial infarction. Tex Heart Inst J 34: 305-309
56. Cooper LT et al. (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: A scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 116: 2216-2233
57. Chow LH et al. (1989) Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. J Am Coll Cardiol 14: 915-920
58. Hauck AJ et al. (1989) Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. Mayo Clin Proc 64: 1235-1245
59. Aretz HT et al. (1987) Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1: 3-14
60. Shanes JG et al. (1987) Interobserver variability in the pathologic interpretation of endomyocardial biopsy results. Circulation 75: 401-405
61. Lieberman EB et al. (1991) Clinicopathologic description of myocarditis. J Am Coll Cardiol 18: 1617-1626
62. Acker MA (2001) Mechanical circulatory support for patients with acute-fulminant myocarditis. Ann Thorac Surg 71 (suppl): S73-S76
63. Dipla K et al. (1998) Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation 97: 2316-2322
64. Zafeiridis A et al. (1998) Regression of cellular hypertrophy after left ventricular assist device support. Circulation 98 656-662
65. Reiss N et al. (1996) Management of acute fulminant myocarditis using circulatory support systems. Artif Organs 20: 964-970
66. Kawahito K et al. (1998) Usefulness of extracorporeal membrane oxygenation for treatment of fulminant myocarditis and circulatory collapse. Am J Cardiol 82: 910-911
67. Bavaria JE et al. (1990) Effect of circulatory assist devices on stunned myocardium. Ann Thorac Surg 49: 123-128
68. Matsumori A et al. (1999) High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: A possible mechanism of digitalis toxicity. Jpn Circ J 63: 934-940
69. Houel R et al. (1999) Myocardial recovery after mechanical support for acute myocarditis: Is sustained recovery predictable? Ann Thorac Surg 68: 2177-2180
70. Parrillo JE et al. (1989) A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 321: 1061-1068
71. Miric M et al. (1996) Long-term follow up of patients with dilated heart muscle disease treated with human leucocytic interferon alpha or thymic hormones initial results. Heart 75: 596-601
72. Wojnicz R et al. (2001) Randomized, placebocontrolled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 104: 39-45
73. Gullestad L et al. (2001) Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 103: 220-225
74. McNamara DM et al. (2001) Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 103: 2254-2259
75. Maisch B et al. (2004) Treatment of inflammatory dilated cardiomyopathy and (peri)myocarditis with immunosuppression and i.v. immunoglobulins. Herz 29: 624-636
76. Bergelson JM et al. (1997) Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320-1323
77. Liu PP et al. (2001) Advances in the understanding of myocarditis. Circulation 104: 1076-1082
78. Neu N et al. (1987) Cardiac myosin induces myocarditis in genetically predisposed mice. J Immunol 139: 3630-3636
79. Neu N et al. (1987) Autoantibodies specific for the cardiac myosin isoform are found in mice susceptible to coxsackievirus B3-induced myocarditis. J Immunol 138: 2488-2492
80. Wang Y et al. (2000) Nasal administration of cardiac myosin suppresses autoimmune myocarditis in mice. J Am Coll Cardiol 36 1992-1999